We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
By Tapan Panchal
LONDON--Pharmaceutical company AstraZeneca PLC (AZN.LN) said Tuesday the U.S. Food and Drug Administration accepted a complete re-submission of a new drug application for a potential new medicine for treating high potassium levels in the human body.
The regulator accepted a new application for sodium zirconium cyclosilicate, or ZS-9, used for treating hyperkalaemia, it said. The new application was submitted by the company's unit ZS Pharma.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
October 18, 2016 02:45 ET (06:45 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions